Key Contraindications (Both) Active malignancy or recent cancer history, pregnancy, breastfeeding, uncontrolled diabetes, severe pituitary disease
Copper peptide results follow a predictable timeline, though individual variation exists based on age, skin condition, and protocol intensity
BPC-157 isn't a recognised pharmaceutical ingredient in the United States
Combination Therapy Research (CagriSema) The synergistic combination of cagrilintide with semaglutide represents a novel approach in multi-agonist metabolic therapeutics [7] : REDEFINE 1 Trial Highlights Primary Efficacy CagriSema: -15.6% weight loss at 32 weeks [7] Cagrilintide alone: -10.8% Placebo: -2.4% Responder Rates 10% weight loss: 74% (CagriSema) 15% weight loss: 52% (CagriSema) 20% weight loss: 32% (CagriSema) Research Applications: Investigation of multi-receptor agonism strategies in metabolic regulation Study of synergistic vs
We believe in a full holistic approach and will guide you to chat to your treating physician when needed who can also do a referral for you
Use the dosage chart below as an educational overview only